Moderna's stock recently hit a new 52-week high after receiving positive news surrounding one of its vaccines.

Moderna (MRNA) closed at $55.63 in the latest trading session, marking a +2.89% move from the prior day. This change outpaced ...

A fresh era of earnings growth may be on the horizon.

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking at therapeutics stocks, starting with ...

Moderna (MRNA) drew fresh attention after appointing experienced financial executive Michael McDonnell to its Board and Audit ...

CAMBRIDGE, MA / ACCESS Newswire / July 16, 2026 / Moderna, Inc. (NASDAQ:MRNA) today announced the dosing of the first ...

Now, it’s worth noting Stock Advisor’s total average return is 892 % — a market-crushing outperformance compared to 206% for ...

CAMBRIDGE, MA / ACCESS Newswire / / Moderna, Inc. (NASDAQ:MRNA), today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Friday, July 31, 2026 to report its second ...

Moderna said it plans to slash roughly 10% of its global workforce by the end of the year, as Covid shot sales continue to dwindle and the company grapples with uncertainty in the vaccine market. In a ...

Alex Hogan is STAT’s senior multimedia producer and host of STATus Report, STAT’s weekly video series. You can follow him on Bluesky. The story of the biotech company Moderna almost reads like a ...

Moderna's growth story is just beginning.

Moderna has countered a patent-infringement lawsuit brought by biotech company CureVac in Delaware federal court over its blockbuster COVID-19 shots, arguing that the lawsuit breaks an agreement ...